A prospective meta-analysis of international randomized clinical trials (RCTs) of convalescent plasma for the treatment of hospitalized COVID-19 patients finds no clinical benefit in most cases.Convalescent plasma, considered an experimental treatment by the US Food and Drug Administration (FDA), is donated by COVID-19 survivors in the hope that recipients with current infections benefit from the anti–SARS-CoV-2 antibodies.
On Dec 28, 2021, the FDA restricted the use of convalescent plasma to patients with impaired immune systems.Mild to moderately ill and mechanical ventilation not neededIn the study, published yesterday in JAMA Network Open, a team led by NYU Grossman School of Medicine researchers evaluated and modeled individual patient data in real time from eight RTCs enrolling 2,341 participants from May to August 2020.
The RCTs were conducted in the United States, Belgium, Brazil, India, the Netherlands, and Spain; two were double-blinded, and six were open-label, while three were single-site and five were multicenter.Participants, who were hospitalized but did not require mechanical ventilation, were randomly assigned to receive either COVID-19 convalescent plasma (CCP, 1,231) or control (standard care or placebo,1,138).
Primary outcome data were monitored until April 2021.Median patient age was 60 years, 35.7% were women, and more than half were randomized 4 to 10 days after symptom onset.